Every 10-Q that Galectin Therapeutics Inc. (GALT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GALT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GALT filings page.
Galectin Therapeutics Inc. reports it remains a clinical-stage company with no revenue and continuing losses. For the six months ended June 30, 2026, net loss was $14,159 (in thousands), improving from $17,152 (in thousands) in 2025, as research and development expenses fell to $4,366 (in thousands) from $9,746 (in thousands).
Cash and cash equivalents were $13,269 (in thousands), and management expects existing cash plus a related-party credit line to fund operations through June 2027. However, substantial doubt is raised about the ability to continue as a going concern beyond 12 months from issuance without additional capital. The balance sheet shows a significant stockholders’ deficit of $138,575 (in thousands) and large related-party convertible debt and derivative liabilities.
The company discloses detailed terms of multiple convertible notes and credit facilities from its chairman and significant fair value increases in related derivative liabilities. A subsequent event on July 31, 2026 converted $91,000,000 of principal and $14,806,981 of accrued interest under these facilities into 34,376,167 common shares, extinguishing that debt. Galectin also discusses NAVIGATE Phase 2b/3 trial results for belapectin in MASH cirrhosis, noting mixed primary outcomes but favorable per-protocol and U.S. subgroup data, alongside a continued focus on partnering and future oncology development subject to financing.
Galectin Therapeutics Inc. reported a Q1 2026 net loss of $5.0 million, improved from $9.6 million a year earlier, as research and development spending declined sharply. Operating expenses fell to $4.1 million from $7.9 million, mainly from lower research and development costs.
Cash and cash equivalents were $14.1 million as of March 31, 2026, down from $17.7 million at year-end, with net cash used in operating activities of $3.9 million. The company also relies on substantial related-party financing, including convertible notes and a convertible line of credit with total borrowings and accrued interest of over $100 million, all generally convertible into common stock.
Management describes Galectin as a clinical stage biopharmaceutical company with no revenue, focused on galectin-3 inhibition for fibrotic disease and cancer. Following top-line results from its NAVIGATE trial in MASH cirrhosis, the company highlights reduced portal hypertension and biomarker improvements in certain subgroups, while noting the primary composite endpoint was not met in the overall intent-to-treat population. Management believes existing cash and an available $10 million undrawn line of credit can fund currently planned operations through May 2027.
Galectin Therapeutics (GALT) filed its Q3 2025 10‑Q, reporting a net loss of $8.184M for the quarter and $25.336M for the nine months. Operating expenses for the nine months fell to $16.720M from $30.005M a year ago as R&D tapered with trial activity.
Cash and equivalents were $11.525M at Sept 30, 2025. Net cash used in operations was $17.833M, partly offset by $14.238M from financing, including related‑party credit draws and $2.071M via the at‑the‑market program. The company states substantial doubt about its ability to continue as a going concern, though it believes existing cash and a new $10M line of credit signed on July 8, 2025 can fund planned operations through June 30, 2026.
Total assets were $12.865M against liabilities of $136.445M, resulting in a stockholders’ deficit of $125.303M. The NAVIGATE trial’s top‑line showed a 49.3% variceal incidence reduction in the per‑protocol population at 2 mg/kg (p<0.05); U.S. completers saw a 68.1% reduction (p=0.02). Safety remained comparable to placebo with no drug‑related SAEs reported.
Galectin Therapeutics reported cash of $13.771 million and a six-month net loss of $17.152 million. Operating expenses for the six months fell to $12.522 million from $20.939 million a year earlier, driven by lower research and development spending ($9.746 million versus $17.867 million). Net cash used in operating activities improved to $14.291 million from $20.438 million. The balance sheet shows total liabilities of $132.769 million and stockholders' deficit of $(118.890 million), including $88.150 million of borrowings and accrued interest under related-party convertible lines of credit and $1.537 million of derivative liabilities. Management discloses substantial doubt about the company’s ability to continue as a going concern but states available credit and a new related-party $10 million supplemental line provide belief that planned operations can be funded through June 30, 2026.